ICU nurses may look to AI for relief from alarm fatigue

Not only is AI aiding recovery for some of the sickest hospitalized patients—those in the ICU—but it’s also making work less stressful for the medical professionals who care for them.

NBC News’s online science and innovation section, Mach, posted a consumer-level update on these developments July 27.

One of the best benefits coming from ongoing AI analysis of ICU patients’ vital signs is a reduction in “alarm fatigue,” according to the article.

This phenomenon is common among nurses and other healthcare workers. It often manifests as a tuning-out of all the beeps, buzzes and clicks constantly emanating from myriad bedside monitors. That includes the ones that might be signaling true emergencies.

Mach contributor Sony Salzman points out that alarm-related problems—likely including deliberate if well-intentioned shutoffs—contributed to more than 500 patient deaths from 2005 to 2008.

Today’s AI assistants in the ICU “can ignore false red flags and focus on meaningful patterns that indicate real risk,” Salzman reports. “As a bonus, AI models can hunt for meaningful patterns among massive databases of electronic medical records—absorbing far more data than a human would ever be able to review.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.